Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empliciti (Elotuzumab) Postmarketing Surveillance in Korean Patients With Multiple Myeloma

NCT03660072 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03660072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03660072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empliciti (Elotuzumab) Postmarketing Surveillance in Korean Patients With Multiple Myeloma
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Withdrawn
Start date
January 31, 2022
Completion date
October 28, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma